111 related articles for article (PubMed ID: 38862983)
1. Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy.
Wang Y; Vandewalle N; De Veirman K; Vanderkerken K; Menu E; De Bruyne E
Cell Commun Signal; 2024 Jun; 22(1):320. PubMed ID: 38862983
[TBL] [Abstract][Full Text] [Related]
2. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
3. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V; Kumar S
Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
[TBL] [Abstract][Full Text] [Related]
4. The complex network of mTOR signalling in the heart.
Sciarretta S; Forte M; Frati G; Sadoshima J
Cardiovasc Res; 2022 Jan; 118(2):424-439. PubMed ID: 33512477
[TBL] [Abstract][Full Text] [Related]
5. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
Li J; Zhu J; Cao B; Mao X
Curr Pharm Des; 2014; 20(1):125-35. PubMed ID: 24001224
[TBL] [Abstract][Full Text] [Related]
6. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
[TBL] [Abstract][Full Text] [Related]
7. mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process.
Marafie SK; Al-Mulla F; Abubaker J
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892329
[TBL] [Abstract][Full Text] [Related]
8. Drug discovery targeting the mTOR pathway.
Martelli AM; Buontempo F; McCubrey JA
Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
[TBL] [Abstract][Full Text] [Related]
9. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.
Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
[TBL] [Abstract][Full Text] [Related]
10. Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its Partners to Overcome Metastasis and Drug Resistance.
Butt G; Shahwar D; Qureshi MZ; Attar R; Akram M; Birinci Y; Karatoprak GS; Gasparri ML; Farooqi AA
Adv Exp Med Biol; 2019; 1152():283-292. PubMed ID: 31456190
[TBL] [Abstract][Full Text] [Related]
11. Dynamic modeling of signal transduction by mTOR complexes in cancer.
Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
[TBL] [Abstract][Full Text] [Related]
12. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
Lu X; Paliogiannis P; Calvisi DF; Chen X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):49-61. PubMed ID: 32394479
[TBL] [Abstract][Full Text] [Related]
13. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.
Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1322-1337. PubMed ID: 30928610
[TBL] [Abstract][Full Text] [Related]
14. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
15. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
Yoon MS
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077002
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of mTOR Signaling after Brain Ischemia.
Villa-González M; Martín-López G; Pérez-Álvarez MJ
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269956
[TBL] [Abstract][Full Text] [Related]
17. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
18. Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications.
Yang L; Zhang Z; Wang D; Jiang Y; Liu Y
Curr Drug Targets; 2022; 23(7):692-710. PubMed ID: 35021971
[TBL] [Abstract][Full Text] [Related]
19. Control of B lymphocyte development and functions by the mTOR signaling pathways.
Iwata TN; Ramírez-Komo JA; Park H; Iritani BM
Cytokine Growth Factor Rev; 2017 Jun; 35():47-62. PubMed ID: 28583723
[TBL] [Abstract][Full Text] [Related]
20. Growth or death? Control of cell destiny by mTOR and autophagy pathways.
Khalil MI; Ali MM; Holail J; Houssein M
Prog Biophys Mol Biol; 2023 Dec; 185():39-55. PubMed ID: 37944568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
